US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
CA2124821C
(en)
|
1991-12-18 |
2003-10-07 |
Isaac Ghebre-Sellassie |
Novel solid pharmaceutical dispersions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
DE69327877T2
(de)
*
|
1992-10-14 |
2000-10-05 |
Nippon Shinyaku Co Ltd |
Verfahren zur verschiebung eines kristallzustandes
|
US5811547A
(en)
*
|
1992-10-14 |
1998-09-22 |
Nippon Shinyaju Co., Ltd. |
Method for inducing crystalline state transition in medicinal substance
|
CA2147283C
(en)
*
|
1992-10-16 |
2007-01-16 |
Kouichi Nakamichi |
Method of manufacturing wax matrices
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
DE69428707T2
(de)
*
|
1993-08-20 |
2002-07-11 |
Nippon Shinyaku Co Ltd |
Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
|
GB2281697A
(en)
|
1993-09-14 |
1995-03-15 |
Euro Celtique Sa |
Laxative compositions in capsules
|
WO1995013794A1
(fr)
*
|
1993-11-18 |
1995-05-26 |
Nippon Shinyaku Co., Ltd. |
Procede pour produire une composition de medicament stable, et preparation pharmaceutique
|
DE19509807A1
(de)
*
|
1995-03-21 |
1996-09-26 |
Basf Ag |
Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5858411A
(en)
*
|
1994-12-19 |
1999-01-12 |
Daiichi Pharmaceutical Co., Ltd. |
Sustained-release granular preparations and production process thereof
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
WO1997004782A1
(fr)
*
|
1995-07-26 |
1997-02-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Dispersion solide ou preparation a dispersion solide de derives xanthine
|
TW487582B
(en)
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
TR199801225T2
(xx)
*
|
1996-05-20 |
1998-11-23 |
Janssen Pharmaceutica N.V. |
Geli�tirilmi� biyolojik kullan�l�rl��a sahip antifungal bile�imler.
|
US6139872A
(en)
*
|
1996-08-14 |
2000-10-31 |
Henkel Corporation |
Method of producing a vitamin product
|
JPH10114682A
(ja)
*
|
1996-10-11 |
1998-05-06 |
Shimizu Kagaku Kk |
グルコマンナン配合持効性内服用薬剤
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
EP1745774A3
(en)
|
1997-08-11 |
2007-04-11 |
Pfizer Products Inc. |
Solid pharmaceutical dispersions with enhanced bioavailability
|
ES2287971T3
(es)
*
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
US6013280A
(en)
*
|
1997-10-07 |
2000-01-11 |
Fuisz Technologies Ltd. |
Immediate release dosage forms containing microspheres
|
WO1999034780A1
(de)
*
|
1998-01-12 |
1999-07-15 |
Bühler AG |
Verfahren und vorrichtung zum verkapseln von wirkstoffen
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
ES2273493T3
(es)
*
|
1998-05-27 |
2007-05-01 |
Euro-Celtique S.A. |
Uso de preparados para la aplicacion de agentes antisepticos y/o agentes que favorecen la curacion de heridas al tracto respiratorio inferior.
|
DE19842753A1
(de)
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
DE19842914A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Basf Ag |
Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US6455526B1
(en)
|
1998-12-16 |
2002-09-24 |
Aventis Pharmaceuticals, Inc. |
Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
|
HU226586B1
(en)
*
|
1998-12-16 |
2009-04-28 |
Aventis Pharma Inc |
Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
|
EP1970052A2
(en)
|
1999-02-09 |
2008-09-17 |
Pfizer Products Inc. |
Basic drug compositions with enhanced bioavailability
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
ATE400252T1
(de)
*
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
JP2000281561A
(ja)
*
|
1999-03-26 |
2000-10-10 |
Ajinomoto Co Inc |
新規溶媒法固体分散体製剤
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US7297344B1
(en)
|
1999-05-27 |
2007-11-20 |
Euro-Celtique, S.A. |
Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
|
US7300667B1
(en)
|
1999-05-27 |
2007-11-27 |
Euro-Celtique, S.A. |
Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
|
BR0010983A
(pt)
|
1999-05-27 |
2002-03-05 |
Euro Celtique Sa |
Preparações para a aplicação de agentes antiinflamatórios
|
DE19945982A1
(de)
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
DE19949897A1
(de)
*
|
1999-10-15 |
2001-04-19 |
Rainer Rogasch |
Formkörper und Verfahren zu dessen Herstellung
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
ATE329579T1
(de)
|
1999-11-12 |
2006-07-15 |
Abbott Lab |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
CA2395331C
(en)
|
1999-12-23 |
2009-01-06 |
Pfizer Products Inc. |
Pharmaceutical compositions providing enhanced drug concentrations
|
RU2277416C2
(ru)
*
|
2000-03-21 |
2006-06-10 |
Ниппон Синяку Ко., Лтд. |
Препараты для перорального введения с замедленным высвобождением
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
DE10031044A1
(de)
|
2000-06-26 |
2002-01-03 |
Bayer Ag |
Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
|
MXPA03000520A
(es)
*
|
2000-07-17 |
2003-10-06 |
Yamanouchi Pharma Co Ltd |
Composicion farmaceutica mejorada en absorbabilidad peroral..
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
WO2002024168A1
(fr)
*
|
2000-09-25 |
2002-03-28 |
Nippon Shinyaku Co., Ltd. |
Procede de production d'une dispersion solide medicinale
|
CN100518827C
(zh)
|
2000-10-30 |
2009-07-29 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
ITMI20010141A1
(it)
*
|
2001-01-26 |
2002-07-26 |
Giuliani Spa |
Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
|
GB0104752D0
(en)
*
|
2001-02-27 |
2001-04-18 |
Astrazeneca Ab |
Pharmaceutical compositions
|
DE60206889T2
(de)
*
|
2001-02-27 |
2006-07-27 |
Astrazeneca Ab |
Pharmazeutische formulierung enthaltend bicalutamid
|
US6465014B1
(en)
*
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
DE60233874D1
(de)
|
2001-06-22 |
2009-11-12 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
|
TNSN03137A1
(en)
*
|
2001-06-22 |
2005-12-23 |
Pfizer Prod Inc |
PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
|
MXPA03011935A
(es)
*
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
|
EP1269994A3
(en)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
BR0210520A
(pt)
*
|
2001-06-22 |
2004-06-22 |
Pfizer Prod Inc |
Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
SE0103424D0
(sv)
*
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
WO2003063868A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
KR100664822B1
(ko)
|
2002-02-01 |
2007-01-04 |
화이자 프로덕츠 인코포레이티드 |
변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
|
AR038375A1
(es)
*
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
US20030204180A1
(en)
*
|
2002-04-30 |
2003-10-30 |
Kimberly-Clark Worldwide, Inc. |
Temperature responsive delivery systems
|
CN1681479A
(zh)
*
|
2002-08-12 |
2005-10-12 |
辉瑞产品公司 |
半有序药物和聚合物的药物组合物
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
WO2004069180A2
(en)
*
|
2003-01-31 |
2004-08-19 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
BRPI0407181A
(pt)
*
|
2003-02-03 |
2006-02-07 |
Novartis Ag |
Formulação farmacêutica
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
CN1878538A
(zh)
*
|
2003-11-14 |
2006-12-13 |
辉瑞产品公司 |
用于治疗肥胖的mtp抑制剂的固体无定形分散体
|
BRPI0417492A
(pt)
*
|
2003-12-09 |
2007-05-29 |
Pfizer |
composições compreendendo um inibidor de protease de hiv
|
GEP20084360B
(en)
|
2004-02-04 |
2008-04-29 |
Pfizer Prod Inc |
Substituted quinoline compounds
|
US20050238721A1
(en)
*
|
2004-04-07 |
2005-10-27 |
Acquarulo Lawrence A Jr |
One step compounding extrusion of drug filled polymers
|
CA2560165A1
(en)
*
|
2004-05-04 |
2005-11-10 |
Boehringer Ingelheim International Gmbh |
Solid pharmaceutical form comprising an ltb4 antagonist
|
AU2005247693A1
(en)
|
2004-05-25 |
2005-12-08 |
Pfizer Products Inc. |
Tetraazabenzo[E]azulene derivatives and analogs thereof
|
DE602005010074D1
(de)
*
|
2004-05-28 |
2008-11-13 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
WO2006073973A2
(en)
*
|
2004-12-31 |
2006-07-13 |
Reddy Us Therapeutics, Inc. |
Novel benzylamine derivatives as cetp inhibitors
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
KR101409302B1
(ko)
*
|
2005-08-02 |
2014-06-20 |
드로싸팜 아게 |
인도메타신 및/또는 아세메타신을 포함하는 약학적 조성물
|
AU2006294581B2
(en)
|
2005-09-27 |
2011-11-03 |
Tissuetech, Inc. |
Amniotic membrane preparations and purified compositions and methods of use
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
KR101405545B1
(ko)
|
2005-11-28 |
2014-07-03 |
마리누스 파마슈티컬스 |
ganaxolone 제형, 이의 제조방법 및 용도
|
EP1832281A1
(en)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Process for producing a solid dispersion of an active ingredient
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
DK2081435T3
(en)
|
2006-09-22 |
2016-08-15 |
Pharmacyclics Llc |
INHIBITORS OF BRUTON'S TYROSINKINASE
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US7607596B1
(en)
|
2007-03-07 |
2009-10-27 |
Exxpharma, LLC |
Process for enhancing the solubility of poorly soluble drugs
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
WO2008149192A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CN101754962B
(zh)
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
CN101835492B
(zh)
*
|
2007-08-21 |
2012-11-21 |
德克萨斯州立大学董事会 |
用于制药应用的热动力学混合
|
MX2010002712A
(es)
|
2007-09-10 |
2010-06-09 |
Calcimedica Inc |
Compuestos que modulan calcio intracelular.
|
EP2191830A4
(en)
*
|
2007-09-21 |
2011-11-23 |
Shionogi & Co |
SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
|
HUE043897T2
(hu)
|
2007-09-25 |
2019-09-30 |
Solubest Ltd |
Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
|
WO2009053635A1
(fr)
*
|
2007-10-11 |
2009-04-30 |
L'oreal |
Composition cosmetique structuree
|
FR2922100B1
(fr)
*
|
2007-10-11 |
2009-12-11 |
Oreal |
Procede de preparation de particules semi-solides a interet cosmetique
|
EP2240162A4
(en)
|
2007-12-06 |
2013-10-09 |
Bend Res Inc |
NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
|
WO2009073215A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
US20100048913A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
DK2280704T3
(en)
*
|
2008-03-31 |
2015-06-29 |
Cymabay Therapeutics Inc |
Oxymethylenarylforbindelser and uses thereof
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
US20110312916A1
(en)
|
2009-02-05 |
2011-12-22 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
ES2552386T3
(es)
|
2009-04-03 |
2015-11-27 |
F. Hoffmann-La Roche Ag |
Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
|
DK2421901T3
(en)
|
2009-04-24 |
2016-01-11 |
Tissue Tech Inc |
Compositions comprising HC-HA complex, and methods of use thereof
|
ES2769357T3
(es)
|
2009-06-16 |
2020-06-25 |
Pfizer |
Formas farmacéuticas de apixaban
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
CA2775840C
(en)
|
2009-10-01 |
2018-02-06 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
JP2013510166A
(ja)
|
2009-11-06 |
2013-03-21 |
プレキシコン インコーポレーテッド |
キナーゼ調節のための化合物、方法およびその適用
|
BR112012018818A2
(pt)
*
|
2010-03-26 |
2016-04-12 |
Dow Global Technologies Llc |
processo para produzir um filme extrudado de fundido e filme de extrudado de fundido
|
EP2552402B1
(en)
*
|
2010-03-26 |
2016-11-23 |
Dow Global Technologies LLC |
Multilayer melt-extruded film
|
BR112012018523A2
(pt)
*
|
2010-03-26 |
2019-09-24 |
Dow Global Technologies Llc |
película em monocamada ou multicada e processo para produzir uma película extrudada sob fusão
|
WO2011130689A1
(en)
|
2010-04-15 |
2011-10-20 |
Tracon Pharmaceuticals, Inc. |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
EP2563759B1
(en)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2011145022A1
(en)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phenyl benzoylamides
|
KR101580714B1
(ko)
|
2010-06-03 |
2016-01-04 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 인산화효소(btk)의 억제제의 용도
|
CN103037843A
(zh)
*
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
WO2012003350A1
(en)
|
2010-07-02 |
2012-01-05 |
The Procter & Gamble Company |
Methods of delivering a health care active by administering personal health care articles comprising a filament
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
KR20140006879A
(ko)
|
2011-02-17 |
2014-01-16 |
에프. 호프만-라 로슈 아게 |
고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
DE102011015370A1
(de)
*
|
2011-03-29 |
2012-10-04 |
Emodys Gmbh |
Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
ES2822301T3
(es)
|
2011-06-10 |
2021-04-30 |
Tissuetech Inc |
Métodos de procesamiento de tejidos de soporte fetal
|
CN103827105B
(zh)
|
2011-08-18 |
2016-08-17 |
雷迪博士实验室有限公司 |
作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
|
RU2609833C2
(ru)
|
2011-09-13 |
2017-02-06 |
Фармасайкликс Элэлси |
Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
|
CN103958511A
(zh)
|
2011-09-27 |
2014-07-30 |
雷迪博士实验室有限公司 |
作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
KR101653473B1
(ko)
|
2012-01-06 |
2016-09-01 |
어바이드 테라퓨틱스, 인크. |
카르바메이트 화합물 및 그의 제조 및 이용 방법
|
EP2822539B1
(en)
|
2012-03-07 |
2018-11-21 |
National Institute Of Pharmaceutical Education And Research (NIPER) |
Nanocrystalline solid dispersion compositions
|
CN104334557A
(zh)
|
2012-04-06 |
2015-02-04 |
辉瑞公司 |
二酰基甘油酰基转移酶2抑制剂
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
CA3218491A1
(en)
|
2012-06-04 |
2013-12-12 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
ES2846789T3
(es)
|
2012-07-11 |
2021-07-29 |
Tissuetech Inc |
Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
|
DK2900674T3
(en)
|
2012-09-28 |
2017-07-03 |
Univ Washington Through Its Center For Commercialization |
RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
CA2891502A1
(en)
|
2012-11-19 |
2014-05-22 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of cetp inhibitors
|
JP6150518B2
(ja)
|
2012-12-27 |
2017-06-21 |
花王株式会社 |
ポリフェノール組成物の製造方法
|
WO2014128564A2
(en)
|
2013-02-21 |
2014-08-28 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of cetp inhibitors
|
US9884067B2
(en)
|
2013-03-14 |
2018-02-06 |
University Of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
EP2837391B1
(en)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
|
WO2015023710A1
(en)
|
2013-08-12 |
2015-02-19 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
WO2015034889A2
(en)
|
2013-09-04 |
2015-03-12 |
Zzyzx Polymers LLC |
Methods for increasing throughput rates of solid-state extrusion devices
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20150104508A1
(en)
*
|
2013-10-12 |
2015-04-16 |
Zzyzx Polymers LLC |
Devices, compositions, and methods for fabricating drug delivery systems
|
KR20160093675A
(ko)
|
2013-12-05 |
2016-08-08 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나제의 억제제
|
SI3104853T1
(sl)
|
2014-02-10 |
2020-03-31 |
Respivant Sciences Gmbh |
Zdravljenje s stabilizatorji mastocitov za sistemske motnje
|
EP3725311A1
(en)
|
2014-02-10 |
2020-10-21 |
Respivant Sciences GmbH |
Methods for the treatment of lung diseases with mast cell stabilizers
|
AU2015233094B2
(en)
|
2014-03-17 |
2017-04-27 |
Pfizer Inc. |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
EP3120871B1
(en)
*
|
2014-03-18 |
2023-06-28 |
Takeda Pharmaceutical Company Limited |
Solid dispersion
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US10894058B2
(en)
|
2014-08-29 |
2021-01-19 |
Kao Corporation |
Method for producing solid dispersion containing hardly soluble polyphenol
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
CA2964068A1
(en)
*
|
2014-09-19 |
2016-03-24 |
Board Of Regents, The University Of Texas System |
Methods of preparing extrudates
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
ES2760373T3
(es)
|
2015-02-06 |
2020-05-13 |
Univ Washington |
Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
CA2977521C
(en)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
|
BR122023020985A2
(pt)
|
2015-03-03 |
2023-12-26 |
Pharmacyclics Llc |
Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016183097A1
(en)
|
2015-05-11 |
2016-11-17 |
Abide Therapeutics, Inc. |
Methods of treating inflammation or neuropathic pain
|
CN107847526A
(zh)
|
2015-05-20 |
2018-03-27 |
组织技术公司 |
用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
|
EA038013B1
(ru)
|
2015-05-28 |
2021-06-23 |
Др. Редди'С Лабораториз Лтд. |
Пероральная композиция целекоксиба для лечения боли
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
JP2018525411A
(ja)
|
2015-08-31 |
2018-09-06 |
ファーマサイクリックス エルエルシー |
多発性骨髄腫を治療するためのbtk阻害剤の組み合わせ
|
EP3827838B1
(en)
|
2015-12-16 |
2023-06-07 |
The Walter and Eliza Hall Institute of Medical Research |
Inhibition of cytokine-induced sh2 protein in nk cells
|
EP3405177A1
(en)
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica NV |
Formulations/compositions comprising a btk inhibitor
|
AU2017208473B2
(en)
|
2016-01-19 |
2022-04-21 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a BTK inhibitor
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CN116509869A
(zh)
|
2016-04-04 |
2023-08-01 |
希诺皮亚生物科学公司 |
使用曲匹地尔治疗锥体外系综合征
|
EP3454945B1
(en)
|
2016-05-12 |
2022-01-19 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
KR102388870B1
(ko)
|
2016-05-13 |
2022-04-20 |
메르크 파텐트 게엠베하 |
가소제로서의 아미노 당의 용도
|
KR20230151062A
(ko)
|
2016-05-13 |
2023-10-31 |
메르크 파텐트 게엠베하 |
용융 압출 적용을 위한 중합체의 입자 크기 및 분포
|
WO2017205534A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2018005552A1
(en)
|
2016-06-27 |
2018-01-04 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
CN113214198B
(zh)
|
2016-07-18 |
2022-12-23 |
广州瑞安博医药科技有限公司 |
用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
|
AU2017305392A1
(en)
|
2016-08-03 |
2019-02-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
SG11201901679XA
(en)
|
2016-08-26 |
2019-03-28 |
Curtana Pharmaceuticals Inc |
Inhibition of olig2 activity
|
CN110139646A
(zh)
|
2016-08-31 |
2019-08-16 |
瑞思皮万特科学有限责任公司 |
用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
|
AU2017339366A1
(en)
|
2016-10-07 |
2019-04-11 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of pulmonary fibrosis
|
AU2017352556A1
(en)
|
2016-11-07 |
2019-06-20 |
Merck Patent Gmbh |
Controlled release tablet based on polyvinyl alcohol and its manufacturing
|
WO2018083113A1
(en)
|
2016-11-07 |
2018-05-11 |
Merck Patent Gmbh |
Instant release capsule based on hot melt extruded polyvinyl alcohol
|
JP2019533699A
(ja)
|
2016-11-07 |
2019-11-21 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
ポリビニルアルコールを基にする抗アルコール誘発性用量ダンピング錠剤
|
JOP20190108B1
(ar)
|
2016-11-16 |
2023-09-17 |
H Lundbeck As |
تركيبات صيدلانية
|
MA46866B1
(fr)
|
2016-11-16 |
2021-11-30 |
H Lundbeck As |
Une forme cristalline d'un inhibiteur de magl
|
US11312713B2
(en)
|
2017-03-10 |
2022-04-26 |
Pfizer Inc. |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
|
CN109320428A
(zh)
*
|
2017-08-01 |
2019-02-12 |
浙江普利药业有限公司 |
一种马来酸曲美布汀晶型及其制备方法
|
US11779573B2
(en)
|
2017-09-01 |
2023-10-10 |
University Of Washington |
Crystalline forms of compounds for preventing or treating sensory hair cell death
|
US11382897B2
(en)
|
2017-11-07 |
2022-07-12 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
EP3706736A4
(en)
|
2017-11-10 |
2021-08-11 |
The Regents of the University of Michigan |
ASH1L DEGRADATION AGENTS AND METHODS OF TREATMENT THROUGH THEM
|
CA3084809A1
(en)
|
2017-12-07 |
2019-06-13 |
The Regents Of The University Of Michigan |
Nsd family inhibitors and methods of treatment therewith
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
JP2021527064A
(ja)
|
2018-06-07 |
2021-10-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Prc1阻害剤及びそれを用いた治療方法
|
AU2019310118A1
(en)
|
2018-07-27 |
2021-03-11 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic TRPV1 agonists
|
JP2021535112A
(ja)
|
2018-08-20 |
2021-12-16 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
補体d因子の医学的障害の治療のための医薬化合物
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
MX2021002428A
(es)
|
2018-08-31 |
2023-01-02 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
EP3866773A4
(en)
|
2018-10-16 |
2022-10-26 |
Georgia State University Research Foundation, Inc. |
CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
|
WO2020096660A1
(en)
|
2018-11-06 |
2020-05-14 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
SG11202106304RA
(en)
|
2018-12-31 |
2021-07-29 |
Biomea Fusion Llc |
Irreversible inhibitors of menin-mll interaction
|
WO2020160113A1
(en)
|
2019-02-01 |
2020-08-06 |
Myos Rens Technology Inc. |
Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
|
EP3937938A1
(en)
|
2019-03-15 |
2022-01-19 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
EP3883548A4
(en)
*
|
2019-04-08 |
2022-11-09 |
Cosci Med-tech Co. Ltd. |
METHODS FOR IMPROVING THE SOLUBILIZATION OF PHARMACEUTICAL SUBSTANCES AND PRODUCTS THEREOF
|
KR20220003565A
(ko)
|
2019-04-19 |
2022-01-10 |
화이자 인코포레이티드 |
Pah를 치료하기 위한 항증식제
|
EP3972596A1
(en)
|
2019-05-20 |
2022-03-30 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
EP3990452A1
(en)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
AU2021259496A1
(en)
|
2020-04-21 |
2022-11-10 |
H. Lundbeck A/S |
Synthesis of a monoacylglycerol lipase inhibitor
|
PE20231215A1
(es)
|
2020-06-09 |
2023-08-17 |
Pfizer |
Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
|
WO2022010537A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Gas41 inhibitors and methods of use thereof
|
WO2022133064A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
EP4337316A1
(en)
|
2021-05-11 |
2024-03-20 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
EP4346788A2
(en)
|
2021-06-03 |
2024-04-10 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
WO2024084390A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024086613A2
(en)
|
2022-10-19 |
2024-04-25 |
Myos Corp. |
Myogenic compounds
|